

Product Data Sheet

Cas No.:	919091-63-7	Cat. No:	PL03607
Product Name:		RA-9	
Product synonym:	(3E,5E)-3,5-双(4-硝基亚苄基)哌啶-4-酮;化合物RA-9		
Chemical name:	RA-9		
MF:	C19H15N3O5	FW:	365.339504480362
Purity:	≥98%	Batch No.:	-
Storage:			
Structural formula:		0 = N	
λmax:	-	Formulation:	-
Solubility :			
SMILES:	C(/C1C=CC([N+](=O)[O-])=CC=1)=C1/CNC/C(=C\C2C=CC([N+](=O)[O-])=CC=2)/C/1=O		
InChI Code:		-	
InChl Key:			
'	WARNING This product is	not for human or veterinary use.	

Product Description

RA-9 是一种高效选择性蛋白酶体相关 DUBs 抑制剂,具有良好的毒性和抗癌活性。RA-9 阻断泛素依赖性蛋白降解而不影响 20S 蛋白酶体蛋白水解活性。RA-9 选择性诱导卵巢癌细胞株和供体原代培养细胞凋亡。RA-9 诱导卵巢癌细胞内质网应激反应。

生物活性	RA-9 is a potent and selective proteasome-associated deubiquitinating enzymes (DUBs) inhibitor with favorable toxicity profile and anticancer activity. RA-9 blocks ubiquitin-dependent protein degradation without impacting 20S proteasome proteolytic activity. RA-9 selectively induces onset of apoptosis in ovarian cancer cell lines and primary cultures derived from donors. RA-9 induces endoplasmic reticulum (ER)-stress responses in ovarian cancer cells.	
体外研究(In Vitro)	RA-9 (10-30 μ M; 48 hours) inhibits growth of ovarian cancer cell lines and primary cultures. RA-9 (1.25-5 μ M; 18 hours) causes cell cycle arrest and caspase-mediated apoptosis in ovarian cancer cells. RA-9 (5 μ M; 0-24 hours) induces ER-stress responses in ovarian cancer cells. RA-9 (5 μ M; over 24 hours) treatment results with time-dependent accumulation of the cleaved formed of PARP noticeable as early as 8 hours. has not independently confirmed the accuracy of these methods. They are for reference only.	

体内研究(In Vivo)	RA-9 (5 mg/kg; i.p; one-day on, two-days off) inhibits human ovarian cancer cell growth in vivo and prolongs survival in a mouse model for ovarian cancer. has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model:
包装储存	Powder -20°C 3 years; 4°C 2 years
溶解度数据	In Vitro: DMSO: 4.17 mg/mL (11.41 mM; ultrasonic and warming and heat to 80°C)配制储备液